Showing results (111-120 of 136) with videos related to
Sort By:
Pageof 14
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|December 31, 2024
Solvation Dynamics of Thermoresponsive Polymer Films: The Influence of Salt Series in Water and Mixed Water/Methanol AtmospherePeixi Wang, Tianle Zheng, Julija Reitenbach, et al.Nature Communications|January 14, 2026
Insights into the operational stability of wide-bandgap perovskite and tandem solar cells under rapid thermal cyclingKun Sun, Renjun Guo, Qilin Zhou, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2006
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphomaSandra J Strauss, Frank Morschhauser, Juergen Rech, et al.Pediatric Blood & Cancer|March 4, 2015
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2Elizabeth A Raetz, Mitchell S Cairo, Michael J Borowitz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphomaJohn P Leonard, Morton Coleman, Jamie Ketas, et al.British Journal of Haematology|April 8, 2015
The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphomaBeth A Christian, Ming Poi, Jeffrey A Jones, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2015
First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid TumorsAlexander N Starodub, Allyson J Ocean, Manish A Shah, et al.Cancer|May 31, 2017
Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate for the treatment of diverse epithelial cancers: Safety and pharmacokineticsAllyson J Ocean, Alexander N Starodub, Aditya Bardia, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2020
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trialK Kalinsky, J R Diamond, L T Vahdat, et al.Arthritis & Rheumatology (Hoboken, N.J.)|January 31, 2018
Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome: Post Hoc Analyses From the EMBODY TrialsJacques-Eric Gottenberg, Thomas Dörner, Hendrika Bootsma, et al.Pageof 14